Researchers sought to characterize features and outcomes specific to patients with MDS and MPNs with ring sideroblasts and thrombocytosis.
The approval was based on data from the phase 3 PERSIST-2 trial.
Researchers sought to identify features related to failure to reach allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndromes.
Researchers sought to determine the prevalence of frailty among patients with myeloproliferative neoplasms.
Researchers analyzed data from 2 clinical trials to determine how 2 MPN therapies affect symptom burden.
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
There was no difference in overall survival between patients with MDS/CMML and those with AML.
Results of a 10-year retrospective study suggests a higher risk of nonmelanoma skin cancer in patients with PV or MF after ruxolitinib exposure.
Excess all-cause mortality was greater in younger patients with essential thrombocythemia, polycythemia vera, and primary myelofibrosis.
Seroconversion was observed in 99% of patients with chronic myeloid leukemia.
